Skip to main content

Sign up for our newsletter

An illustration of a person doing a finger prick test

Are you interested in:

  • Hearing about the latest type 1 research breakthroughs?
  • Listening to world-class type 1 research scientists talk about their work at a local Type 1 Diabetes Discovery Day?
  • Getting invited to events where you can meet others with type 1?
  • Getting updates on our latest fundraising activities to support cure, prevention and treatment research?
  • Understanding more about how you can get involved with JDRF?

Subscribe to receive JDRF’s e-newsletters and you’ll be the first to know about all of this and more.

We promise to keep your details secure and we won’t share your information with any other organisations. If you decide you’d rather not hear from us then you can unsubscribe at any time.

Keep up to date with the latest type 1 diabetes research, news and events from JDRF.

To sign up, simply complete your details below and click subscribe.

Type 1 diabetes news

Read more
Nina Willer, who used hybrid closed loop technology through pregnancy, and her child.
Treatment research
7 November 2023

Hybrid closed loop technology set to be made available in England and Wales

The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.

Read more
T cell immune system
Research
6 November 2023

New research highlights the effectiveness of immune therapies for type 1 diabetes

The research, which was co-funded by JDRF, reveals that drugs that target the immune system offer very effective and rapid improvements in stabilising blood sugar levels, often within just three months.

Read more
Dr Ify Mordi, lead type 1 diabetes researcher
Clinical trials
25 October 2023

JDRF award £1.5 million grant to University of Dundee for type 1 diabetes clinical trial

The new JDRF-funded clinical trial called SOPHIST will test a drug to help people with type 1 diabetes and heart failure.

Read more
Young person receiving an injection of the immunotherapy drug teplizumab.jpg
Research
18 October 2023

Clinical trial finds teplizumab slows type 1 diabetes in people newly diagnosed 

Results from a clinical trial called the PROTECT study show that teplizumab can preserve beta cell function in children and adolescents newly diagnosed with type 1 diabetes.

Read more
ELSA testing kits to screen for type 1 diabetes in children
Prevention research
16 October 2023

Trial to screen children for type 1 diabetes now available in Northern Ireland

Children in Northern Ireland are now eligible for a trial screening programme that will identify those at high risk of developing type 1 diabetes in the future.

Read more
A hand holding a plastic model of a kidney
Complications
13 October 2023

JDRF commits £1.3 million to investigate medication with the potential to delay kidney complications

Thanks to JDRF supporters, we’ve been able to award a £1.3 million grant to King’s College London (KCL) and Steno Diabetes Center Copenhagen to examine how existing drugs, known as SGLT inhibitors, could delay the progression of kidney disease in people living with type 1 diabetes.

Read more
A woman with type 1 diabetes who is discussing pregnancy with a nurse
Type 1 technology
5 October 2023

New trial shows benefits of hybrid closed loop in pregnancy  

A JDRF-supported trial published in the New England Journal of Medicine and presented at the European Association for the Study of Diabetes conference has shown that hybrid closed loop technology helps pregnant women better manage their blood sugars compared to traditional insulin pumps or multiple daily injections.  

Read more
A graph from the research paper showing that the people with type 1 diabetes who took the antiviral drugs had higher levels of C-peptide (insulin production) than those on the placebo.
Clinical trials
5 October 2023

Antiviral drugs could maintain beta cell function in children newly diagnosed with type 1 diabetes

A clinical trial funded by JDRF suggests that treating children with antiviral drugs when they are first diagnosed with type 1 diabetes could preserve their ability to produce some insulin.